Evidence map›Paper›PMID 36405778›Full record

ArticleAdvanced therapeutics2022

Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes.

Colleen A Roosa, Mingyang Ma, Preeti Chhabra, Kenneth Brayman, Donald Griffin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Colleen A RoosaDepartment of Biomedical Engineering, University of Virginia, 415 Lane Rd, Charlottesville, Virginia 22903, USA.
Mingyang MaDepartment of Surgery, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22903, USA.
Preeti ChhabraDepartment of Surgery, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22903, USA.
Kenneth BraymanDepartment of Surgery, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22903, USA.
Donald GriffinDepartment of Biomedical Engineering, University of Virginia, 415 Lane Rd, Charlottesville, Virginia 22903, USA.
University of Virginia · USMcCormick (United States) · US

Funding

Improving Biomaterial Implant Tolerance with Damage-Associated Molecular Pathway (DAMP) Molecule AttachmentR21EB028971 · NIBIB · UNIVERSITY OF VIRGINIA · PI EWALD, SARAH E., GRIFFIN, DONALD RICHIERI · 2020 to 2022
$634k
NIBIB NIH HHS R21 EB028971
6 · The paper itself

Abstract

Type 1 diabetes (T1D) is caused by the autoimmune loss of insulin-producing beta cells in the pancreas. The only clinical approach to patient management of blood glucose that doesn't require exogenous insulin is pancreas or islet transplantation. Unfortunately, donor islets are scarce and there is substantial islet loss immediately after transplantation due, in part, to the local inflammatory response. The delivery of stem cell-derived beta cells (

Indexed as

cell deliveryhydrogel scaffoldinjectable biomaterialislet deliverytype 1 diabetes

Identifiers

PMID36405778
PMCPMC9674036
OpenAlexW4283768662

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.